Manisha Shah
Ohio State University Comprehensive Cancer Center · Ohio State University · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Manisha Shah as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01811212 · Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid CancerNational Cancer Institute (NCI) · completed · Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Follicular Carcinoma · principal investigator
- Ph1NCT01713972 · Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant TumorsManisha Shah · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00134043 · Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerNational Cancer Institute (NCI) · completed · Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer · principal investigator
- Ph1NCT00112684 · Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid TumorsNational Cancer Institute (NCI) · terminated · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00095693 · Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid CancerNational Cancer Institute (NCI) · terminated · Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer · principal investigator
- Ph2NCT00084461 · Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsNational Cancer Institute (NCI) · terminated · Gastrinoma, Glucagonoma, Insulinoma · principal investigator
- Ph2NCT00084604 · Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNational Cancer Institute (NCI) · completed · Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach · principal investigator
- Ph2NCT00062374 · Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal JunctionNational Cancer Institute (NCI) · completed · Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Targeting RAF and VEGF Signaling in Thyroid CancerR21CA112903 · NCI · OHIO STATE UNIVERSITY · fiscal years 2005 to 2006 · $198,261 awarded in 2006Same name and institution; not confirmed by an ID
- BIOLOGIC MODIFIER THERAPIES IN AIDS MALIGNANCIESU01CA070079 · NCI · OHIO STATE UNIVERSITY · fiscal years 2002 to 2004 · $96,741 awarded in 2004Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Shared Resource 10: Pharmacoanalytical Shared Resource (PhASR)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Mitch A Phelps · fiscal years 2018 to 2026
- UM1CA186705RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01811212
- U01CA076576RePORTER returned no project for this number; it is shown as the registry gives it.
- U01CA099168RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT00084604
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2018 to 2026Named on NCT00062374
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:41 UTC. The ranking covers the 200 most relevant of 400 PubMed records, and a shared surname and initials can bring in a namesake. All 400 on PubMed
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.J Clin Oncol · 20202,449 citationsRCR 111.1
- Everolimus for advanced pancreatic neuroendocrine tumors.N Engl J Med · 20112,271 citationsRCR 60.8
- 2,186 citationsRCR 94.0
- 2,056 citationsRCR 44.7
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.N Engl J Med · 20151,588 citationsRCR 53.1
- 1,524 citationsRCR 53.9
- 1,422 citationsRCR 77.3
- 1,125 citationsRCR 28.4
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.J Clin Oncol · 2020933 citationsRCR 38.9
- Cabozantinib in progressive medullary thyroid cancer.J Clin Oncol · 2013912 citationsRCR 25.7